Alberta Expands Biosimilar Switching With Adalimumab

Canadian Province Adds Humira, Following British Columbia And New Brunswick

Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.

Alberta Canada Flags Cracked Wall
Alberta has expanded its biosimilar switching program with Humira • Source: Alamy

Alberta has become the latest Canadian province to add Humira (adalimumab) to the list of products covered by its biosimilar switching program, following similar recent moves by British Columbia and New Brunswick.

Having introduced its biosimilar switching program back in 2019 – just months after fellow province British Columbia (Also see "

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.